TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Pioglitazone on Insulin Resistance, Insulin Secretion and Atherosclerosis in Renal Allograft Recipients Without History of Diabetes
Brief Summary: The aim of this study was to evaluate the effect of pioglitazone treatment on insulin secretion, insulin resistance, and progression of atherosclerosis in renal allograft recipients without preoperative history of diabetes.


Options:
A: Arm Label: Vildagliptin, 50 mg, peroral; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vildagliptin | Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin, 50 mg, peroral
B: Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 1
D: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Avastin and Chemotherapy Followed by Avastin Alone or in Combination With Tarceva for the Treatment of Metastatic Colorectal Cancer.
Brief Summary: Chemotherapy and bevacizumab is given for 4 months. Patients who have not progressed will continue with maintenance treatment with either bevacizumab (Avastin) alone, or bevacizumab and erlotinib (Tarceva).


Options:
A: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab, Drug: chemotherapy of mFOLFOX6 or FOLFIRI | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: chemotherapy of mFOLFOX6 or FOLFIRI | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: chemotherapy of mFOLFOX6 or FOLFIRI; Assigned to Arm(s): Arm A, Arm B
B: Arm Label: bevacizumab and erlotinib (KRAS WT); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab, erlotinib | Arm Label: bevacizumab (KRAS WT); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: bevacizumab (KRAS mutated); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: low dose capecitabine (KRAS mutated); Type: ACTIVE_COMPARATOR; Interventions: Drug: low dose capecitabine | Intervention Type: DRUG; Name: bevacizumab, erlotinib; Assigned to Arm(s): bevacizumab and erlotinib (KRAS WT) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab (KRAS WT) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab (KRAS mutated) | Intervention Type: DRUG; Name: low dose capecitabine; Assigned to Arm(s): low dose capecitabine (KRAS mutated)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: erlotinib (Tarceva), Drug: bevacizumab (Avastin) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab (Avastin) | Intervention Type: DRUG; Name: erlotinib (Tarceva); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: bevacizumab (Avastin); Assigned to Arm(s): 1, 2
D: Arm Label: 1Capecitabine + bevacizumab + oxaliplatin + cetuximab; Type: EXPERIMENTAL; Interventions: Drug: 1Capecitabine + oxaliplatin + bevacizumab + cetuximab | Arm Label: 21Capecitabine + bevacizumab + oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 21Capecitabine + bevacizumab + oxaliplatin | Intervention Type: DRUG; Name: 21Capecitabine + bevacizumab + oxaliplatin; Assigned to Arm(s): 21Capecitabine + bevacizumab + oxaliplatin | Intervention Type: DRUG; Name: 1Capecitabine + oxaliplatin + bevacizumab + cetuximab; Assigned to Arm(s): 1Capecitabine + bevacizumab + oxaliplatin + cetuximab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Open Label, Randomized Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or ICSI.
Brief Summary: The primary objective of this trial is to investigate the dose -response relationship of a single injection of Org 38286 to initiate multifollicular growth for the first seven days in a controlled ovarian hyperstimulation (COH) protocol for IVF or ICSI.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Buserelin and Pregnyl | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregnyl | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Buserelin and Pregnyl | Arm Label: D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregnyl | Intervention Type: DRUG; Name: Buserelin and Pregnyl; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregnyl; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Buserelin and Pregnyl; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Pregnyl; Assigned to Arm(s): D
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: corifollitropin alfa | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: corifollitropin alfa | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: corifollitropin alfa | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Follitropin beta injection | Intervention Type: DRUG; Name: corifollitropin alfa; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Follitropin beta injection; Assigned to Arm(s): 4
C: Arm Label: Progesterone 5 Weeks; Type: ACTIVE_COMPARATOR; Interventions: Other: Cease progsterone at 5 | Arm Label: Control Group : P4 8 weeks; Type: OTHER; Interventions: Other: control group: progesterone 8 | Intervention Type: OTHER; Name: Cease progsterone at 5; Assigned to Arm(s): Progesterone 5 Weeks | Intervention Type: OTHER; Name: control group: progesterone 8; Assigned to Arm(s): Control Group : P4 8 weeks
D: Arm Label: Oral dydrogesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral dydrogesterone | Arm Label: Crinone 8% vaginal gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crinone 8% gel | Intervention Type: DRUG; Name: Oral dydrogesterone; Assigned to Arm(s): Oral dydrogesterone | Intervention Type: DRUG; Name: Crinone 8% gel; Assigned to Arm(s): Crinone 8% vaginal gel

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AFX01-11: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Correction of Anemia in Patients With Chronic Renal Failure (CRF) Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment
Brief Summary: The purpose of this study was to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease, who are not on dialysis and not on erythropoiesis stimulating agent (ESA) treatment.


Options:
A: Arm Label: Peginesatide; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Epoetin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or Epoetin beta | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide | Intervention Type: DRUG; Name: Epoetin alfa or Epoetin beta; Assigned to Arm(s): Epoetin
B: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)
C: Arm Label: Peginesatide 0.025 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Peginesatide 0.04 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.025 mg/kg | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.04 mg/kg | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AFX01-11: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Correction of Anemia in Patients With Chronic Renal Failure (CRF) Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment
Brief Summary: The purpose of this study was to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease, who are not on dialysis and not on erythropoiesis stimulating agent (ESA) treatment.


Options:
A: Arm Label: Peginesatide 0.025 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Peginesatide 0.04 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.025 mg/kg | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.04 mg/kg | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
B: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)
C: Arm Label: Peginesatide 0.025 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Peginesatide 0.04 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.025 mg/kg | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.04 mg/kg | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa
D: Arm Label: Peginesatide; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin alfa

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Single Center, Open-label Study to Assess Immunogenicity and Safety of 6 Doses of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX®)in Smokers
Brief Summary: Prior clinical trials examined several schedules of a nicotine vaccine (NicVAX) for anti-nicotine antibody responses, and their impact on helping smokers quit. The best schedule so far has been one with doses at weeks 0, 4, 8, 16 and 26. This new study tests whether changing the schedule to weeks 0, 4, 8, 12 and 16 is an improvement for stimulating antibodies to nicotine. Routine vaccine safety information is also collected. Amendment 1 adds a 6th dose at week 26, and extends follow-up through week 52.


Options:
A: Arm Label: NicVAX; Type: EXPERIMENTAL; Interventions: Biological: 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®) | Arm Label: NicVAX Lot 2; Type: EXPERIMENTAL; Interventions: Biological: 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®) | Intervention Type: BIOLOGICAL; Name: 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®); Assigned to Arm(s): NicVAX, NicVAX Lot 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: NicVAX conjugate vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: NicVAX conjugate vaccine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: NicVAX conjugate vaccine | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Biological: NicVAX conjugate vaccine | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: 6; Type: EXPERIMENTAL; Interventions: Biological: NicVAX conjugate vaccine | Intervention Type: BIOLOGICAL; Name: NicVAX conjugate vaccine; Assigned to Arm(s): 1, 2, 3, 4, 6 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 5
C: Arm Label: NicQb vaccine; Type: EXPERIMENTAL; Interventions: Biological: CYT002-NicQb | Arm Label: Placebo vaccine; Type: PLACEBO_COMPARATOR; Interventions: Biological: CYT002-NicQb | Intervention Type: BIOLOGICAL; Name: CYT002-NicQb; Assigned to Arm(s): NicQb vaccine, Placebo vaccine
D: Arm Label: Placebo vaccine; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo vaccine | Arm Label: NicVAX vaccine; Type: EXPERIMENTAL; Interventions: Biological: NicVAX vaccine | Intervention Type: BIOLOGICAL; Name: NicVAX vaccine; Assigned to Arm(s): NicVAX vaccine | Intervention Type: BIOLOGICAL; Name: Placebo vaccine; Assigned to Arm(s): Placebo vaccine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AFX01-13: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Correction of Anemia in Patients With Chronic Renal Failure (CRF) Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment
Brief Summary: The purpose of this study was to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease, who are not on dialysis and not on erythropoiesis stimulating agent (ESA) treatment.


Options:
A: Arm Label: CERA Treatment Once Monthly; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa Once Biweekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa Once Biweekly | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): CERA Treatment Once Monthly
B: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
C: Arm Label: MIRCERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): MIRCERA
D: Arm Label: Peginesatide 0.025 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Peginesatide 0.04 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.025 mg/kg | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.04 mg/kg | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Exploratory Phase III, Randomised, Double-blind, Therapeutic Single Dose-related Effect, Parallel Group Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)
Brief Summary: The purpose of this study is to compare urticaria lesions (size, kinetics) by thermography, volumetry and digital time lapse photography in CU patients treated with desloratadine 5 mg or desloratadine 20 mg. Hypothesis: Updosing of desloratadine (20mg) is more efficient in the treatment of urticarial lesions as compared to standard dosing (5 mg desloratadine).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Levocetirizine; Type: EXPERIMENTAL; Interventions: Drug: Levocetirizine 1.25 mg | Intervention Type: DRUG; Name: Levocetirizine 1.25 mg; Assigned to Arm(s): Levocetirizine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Omalizumab | Arm Label: Omalizumab 75 mg; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab | Arm Label: Omalizumab 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab | Arm Label: Omalizumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab 150 mg, Omalizumab 300 mg, Omalizumab 75 mg, Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: desloratadine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: desloratadine | Intervention Type: DRUG; Name: desloratadine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: desloratadine; Assigned to Arm(s): 2
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Levocetirizine; Type: EXPERIMENTAL; Interventions: Drug: Levocetirizine | Intervention Type: DRUG; Name: Levocetirizine; Assigned to Arm(s): Levocetirizine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness for Postoperative Pain After Laparoscopic Cholecystectomy of 0,5% Bupivacaine-Soaked Tabotamp Placed in the Gallbladder Bed
Brief Summary: Evaluate the efficacy on postoperative pain of the positioning of a 0,5% bupivacaine soaked-tabotamp in gallbladder bed after videolaparoscopic cholecystectomy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: videolaparocholecystectomy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: videolaparocholecystectomy | Arm Label: 3; Type: NO_INTERVENTION; Interventions: Procedure: videolaparocholecystectomy | Intervention Type: PROCEDURE; Name: videolaparocholecystectomy; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: videolaparocholecystectomy; Assigned to Arm(s): 1, 2 | Intervention Type: PROCEDURE; Name: videolaparocholecystectomy; Assigned to Arm(s): 3
B: Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Drug: 0.9% normal saline solution | Arm Label: Subperitoneal injection; Type: EXPERIMENTAL; Interventions: Drug: Bupivocaine | Arm Label: Topical LA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivocaine | Intervention Type: DRUG; Name: Bupivocaine; Assigned to Arm(s): Subperitoneal injection, Topical LA | Intervention Type: DRUG; Name: 0.9% normal saline solution; Assigned to Arm(s): Control
C: Arm Label: Intravenous lidocaine injection group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous lidocaine injection | Arm Label: Intraperitoneal lidocaine irrigation group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intraperitoneal lidocaine irrigation group | Arm Label: Intravenous normal saline group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Intravenous normal saline injection | Intervention Type: DRUG; Name: Intravenous lidocaine injection; Assigned to Arm(s): Intravenous lidocaine injection group | Intervention Type: DRUG; Name: Intraperitoneal lidocaine irrigation group; Assigned to Arm(s): Intraperitoneal lidocaine irrigation group | Intervention Type: DRUG; Name: Intravenous normal saline injection; Assigned to Arm(s): Intravenous normal saline group
D: Arm Label: Saline sham injection; Type: SHAM_COMPARATOR; Interventions: Other: Normal saline | Arm Label: Bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine | Intervention Type: DRUG; Name: Bupivacaine; Assigned to Arm(s): Bupivacaine | Intervention Type: OTHER; Name: Normal saline; Assigned to Arm(s): Saline sham injection

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Extension to the Double-Blind SP513 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease
Brief Summary: The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease


Options:
A: Arm Label: Rotigotine; Type: EXPERIMENTAL; Interventions: Drug: Rotigotine | Intervention Type: DRUG; Name: Rotigotine; Assigned to Arm(s): Rotigotine
B: Arm Label: TT+VR; Type: EXPERIMENTAL; Interventions: Other: TT+VR | Arm Label: TT alone; Type: ACTIVE_COMPARATOR; Interventions: Other: TT alone | Intervention Type: OTHER; Name: TT+VR; Assigned to Arm(s): TT+VR | Intervention Type: OTHER; Name: TT alone; Assigned to Arm(s): TT alone
C: Arm Label: Isradipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isradipine | Arm Label: Placebo (for Isradipine); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Isradipine) | Intervention Type: DRUG; Name: Isradipine; Assigned to Arm(s): Isradipine | Intervention Type: DRUG; Name: Placebo (for Isradipine); Assigned to Arm(s): Placebo (for Isradipine)
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D3, Dietary Supplement: calcium | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: calcium, Other: Placebo | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Arm 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm 2

Answer: A